SecBot SecBot

BMRN

BIOMARIN PHARMACEUTICAL INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001048477 Biotech & Drug Discovery
$57.99 +0.76 (+1.33%)
Nov 16 4:00 PM ET · prev $57.23
Market cap
$11.0B
Large cap
Consensus
Buy
77% Buy or better · 35 analysts
Median target
🔒 Subscribers only
1 year
+6.5%
from $54.46 · Nov 17
30 days
+6.1%
from $54.67
52-week range
$49.67–70.24
−17% from high · low May 18
Avg volume 20D
2.42M
shares / day
Short interest
14.12M
≈7.3% of shares · +17.2%
Days to cover
5.8
at average volume
Insider net
−$4.3M
0 buyers · 3 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 5 exits
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 10 reports · 90 days
Balance 2 bearish · 1 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next FDA decision date, Feb 28, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $4.3M.

  • InstitutionsMIXED

    Q3 2026: 37 added (2 new), 41 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $10.8M.

  • AnalystsBULLISH

    27 of 35 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +17.2% to 14.12M shares. 5.8 days to cover, ≈7.3% of shares.

  • TrendRANGE

    1% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
5
exits
$10.8M
in new stakes · top 1 shown
FundMoveSharesValue
FMR LLCADD7,343,059$440.6M
UBS Group AGADD1,807,248$108.4M
JPMORGAN CHASE & COADD1,049,767$63.5M
RENAISSANCE TECHNOLOGIES LLCADD727,771$43.7M
MACKENZIE FINANCIAL CORPTRIM565,560$33.9M
LOOMIS SAYLES & CO L PTRIM426,014$25.6M
BARCLAYS PLCADD338,897$20.3M
AmundiADD335,551$20.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

35 analysts
Buy 77% rate it Buy or better
Strong Buy10Buy17Hold8Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 4, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 3, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 3, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Nov 3, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Nov 3, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform

Washington

Corporate Lobbying

25 lobbying filings and 9 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$4.3M
sold · 3 insiders
DateInsiderTypeValue
Sep 30, 2026
Friberg Gregory R
EVP, Chief R&D Officer
Sep 30, 2026
TAX W/H$245.2K
Sep 10, 2026
Plenge Robert M
Director
Sep 10, 2026
AWARD6,140 sh
Sep 2, 2026
Davis George Eric
EVP, Chief Legal Officer
Sep 2, 2026
SELL$1.2M
Jun 2, 2026
Ho Maykin
Director
Jun 2, 2026
AWARD7,490 sh
Jun 2, 2026
ANDERSON ELIZABETH M
Director
Jun 2, 2026
AWARD7,490 sh
Jun 2, 2026
CLARK IAN T
Director
Jun 2, 2026
AWARD7,490 sh
Jun 2, 2026
Bodem Barbara W.
Director
Jun 2, 2026
AWARD7,490 sh
Jun 2, 2026
Dere Willard H
Director
Jun 2, 2026
AWARD7,490 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
14,122,815
shares short
+17.2%
vs prior settlement
5.8
days to cover
≈7.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 SEC
BlackRock filed an amended Schedule 13G disclosing beneficial ownership of 19,373,309 shares of BioMarin common stock…
SC 13G/A · Impact 3/10
Nov 2, 2026 SEC
BioMarin reported Q3 2026 total revenues of $1.025B, up 32% YoY, driven by the Amicus acquisition (GALAFOLD and…
8-K · Impact 6/10
Nov 2, 2026 Earnings result
BMRN Q3 2026 Earnings: EPS $0.23 (+89.8% vs est)
Oct 29, 2026 SEC
Three small asset managers added to their BMRN positions in Q3 2026, while one larger institutional holder trimmed…
INST-CLUSTER · Impact 2/10
Sep 30, 2026 Insider
Friberg Gregory R surrendered for taxes 4,086 shares
EVP, Chief R&D Officer @ $60.00 ($245.2K)
Sep 30, 2026 Inst.
FMR LLC · ADD
7,343,059 shares ($440.6M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
1,807,248 shares ($108.4M)
Sep 10, 2026 Insider
Plenge Robert M was granted 6,140 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
16 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 13, 2026
Clinical Trial
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
Phase 2 · TERMINATED
Nov 2, 2026
Earnings result
BMRN Q3 2026 Earnings: EPS $0.23 (+89.8% vs est)
Oct 5, 2026
Press release
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5…
Oct 2, 2026
Press release
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026…
Oct 1, 2026
Clinical Trial
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Phase 3 · TERMINATED

SecBot reports

15 filings · 1 press release · 3 bullish · 2 bearish · 2 mixed · 8 neutral
All BMRN filing & press-release reports (16)